These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22117122)

  • 21. Determinants of students' willingness to accept a measles-mumps-rubella booster vaccination during a mumps outbreak: a cross-sectional study.
    Donkers HW; Hautvast JL; Akkermans RP; Swaan CM; Ruijs WL; Hulscher ME
    BMC Public Health; 2015 Jun; 15():575. PubMed ID: 26092263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014.
    Chang C; Mo X; Hu P; Liang W; Ma H; An Z; Liu J; Zheng H
    Vaccine; 2015 Jun; 33(28):3223-7. PubMed ID: 25989448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perceptions of mumps and MMR vaccination among university students in England: an online survey.
    Bolton-Maggs D; Conrad D; Keenan A; Lamden K; Ghebrehewet S; Vivancos R
    Vaccine; 2012 Jul; 30(34):5081-5. PubMed ID: 22705081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress toward measles and rubella elimination in Egypt.
    El Sayed N; Kandeel N; Barakat I; Moussa I; Alexander JP; Naouri B; Reef SE
    J Infect Dis; 2011 Jul; 204 Suppl 1():S318-24. PubMed ID: 21666180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outbreak of mumps in a school setting, United Kingdom, 2013.
    Aasheim ET; Inns T; Trindall A; Emmett L; Brown KE; Williams CJ; Reacher M
    Hum Vaccin Immunother; 2014; 10(8):2446-9. PubMed ID: 25424953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia.
    Uno Y; Uchiyama T; Kurosawa M; Aleksic B; Ozaki N
    Vaccine; 2012 Jun; 30(28):4292-8. PubMed ID: 22521285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
    Mrozek-Budzyn D; Kiełtyka A; Majewska R
    Pediatr Infect Dis J; 2010 May; 29(5):397-400. PubMed ID: 19952979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S; Friedland LR; Schuind A; Howe B;
    Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument.
    Brown KF; Shanley R; Cowley NA; van Wijgerden J; Toff P; Falconer M; Ramsay M; Hudson MJ; Green J; Vincent CA; Kroll JS; Fraser G; Sevdalis N
    Vaccine; 2011 Feb; 29(8):1700-9. PubMed ID: 21185850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mumps in a boarding school: description of an outbreak and control measures.
    Mackenzie DG; Craig G; Hallam NF; Moore J; Stevenson J
    Br J Gen Pract; 2006 Jul; 56(528):526-9. PubMed ID: 16834879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.